Hostname: page-component-74656f9884-8r8nv Total loading time: 0 Render date: 2026-11-07T13:12:08.740Z Has data issue: false hasContentIssue false

The Efficacy of Novel Commercial Tourniquet Designs for Extremity Hemorrhage Control: Implications for Spontaneous Responder Every Day Carry

Published online by Cambridge University Press:  13 April 2020

Joshua Ellis
Affiliation:
Department of Emergency Medicine, Mayo Clinic, Rochester, MinnesotaUSA
Melissa M. Morrow
Affiliation:
Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MinnesotaUSA
Alec Belau
Affiliation:
Department of Emergency Medicine, Mayo Clinic, Rochester, MinnesotaUSA
Luke S. Sztajnkrycer
Affiliation:
Department of Emergency Medicine, Mayo Clinic, Rochester, MinnesotaUSA
Jeffrey N. Wood
Affiliation:
Department of Emergency Medicine, Mayo Clinic, Rochester, MinnesotaUSA
Tobias Kummer
Affiliation:
Department of Emergency Medicine, Mayo Clinic, Rochester, MinnesotaUSA
Matthew D. Sztajnkrycer*
Affiliation:
Department of Emergency Medicine, Mayo Clinic, Rochester, MinnesotaUSA
*
Correspondence: Matthew D. Sztajnkrycer, MD, PhD, Professor of Emergency Medicine, Mayo Clinic GE-GR-G410, 200 1st Street SW, Rochester, Minnesota55905USA, E-mail: sztajnkrycer.matthew@mayo.edu
Rights & Permissions [Opens in a new window]

Abstract

Introduction:

Tourniquets (TQs) save lives. Although military-approved TQs appear more effective than improvised TQs in controlling exsanguinating extremity hemorrhage, their bulk may preclude every day carry (EDC) by civilian lay-providers, limiting availability during emergencies.

Study Objective:

The purpose of the current study was to compare the efficacy of three novel commercial TQ designs to a military-approved TQ.

Methods:

Nine Emergency Medicine residents evaluated four different TQ designs: Gen 7 Combat Application Tourniquet (CAT7; control), Stretch Wrap and Tuck Tourniquet (SWAT-T), Gen 2 Rapid Application Tourniquet System (RATS), and Tourni-Key (TK). Popliteal artery flow cessation was determined using a ZONARE ZS3 ultrasound. Steady state maximal generated force was measured for 30 seconds with a thin-film force sensor.

Results:

Success rates for distal arterial flow cessation were 89% CAT7; 67% SWAT-T; 89% RATS; and 78% TK (H 0.89; P = .83). Mean (SD) application times were 10.4 (SD = 1.7) seconds CAT7; 23.1 (SD = 9.0) seconds SWAT-T; 11.1 (SD = 3.8) seconds RATS; and 20.0 (SD = 7.1) seconds TK (F 9.71; P <.001). Steady state maximal forces were 29.9 (SD = 1.2) N CAT7; 23.4 (SD = 0.8) N SWAT-T; 33.0 (SD = 1.3) N RATS; and 41.9 (SD = 1.3) N TK.

Conclusion:

All novel TQ systems were non-inferior to the military-approved CAT7. Mean application times were less than 30 seconds for all four designs. The size of these novel TQs may make them more conducive to lay-provider EDC, thereby increasing community resiliency and improving the response to high-threat events.

Information

Type
Original Research
Copyright
© World Association for Disaster and Emergency Medicine 2020
Figure 0

Table 1. Successful Tourniquet Application Rates for Popliteal Artery Flow Cessation

Figure 1

Table 2. Time for Tourniquet Application

Figure 2

Figure 1. Steady-State Maximal Generated Force Measurements for Upper Extremity Tourniquet Applications.

Note: Generated force was measured with a pre-calibrated circular sensor, placed between the skin and the tourniquet at a standardized location on the lateral aspect of the left mid-biceps. Force was measured at 40Hz while the tourniquet was tightened to full application. The steady state maximal generated force was maintained for 30 seconds. A single steady state measurement was recorded for each tourniquet: (A) CAT7; (B) RATS; (C) SWAT-T; and (D) TK.Abbreviations: CAT7, Generation 7 Combat Application Tourniquet; RATS, Generation 2 Rapid Application Tourniquet System; SWAT-T, Stretch Wrap and Tuck Tourniquet; TK, Tourni-Key.